14 matches for your search in the start-up spotlight
rss
10-Mar-2025
Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187.0 million Series A financing round. This financing was led by Frazier Life Sciences with ...
Araris to receive an upfront fee and milestone payments potentially totalling USD 780 million plus royalties on net product sales
15-Jan-2025
Araris Biotech AG, a Swiss oncology biotech spin-off company developing next-generation antibody drug conjugates (ADCs), announced they have entered a Research Collaboration and Option to License Agreement (“RCO”) under which Araris will use its proprietary linker-conjugation platform, AraLinQ™, ...
In successful funding rounds, three LMU spin-offs have brought in investments worth millions.
25-Jun-2024
Tubulis, Smart Reporting, and Eisbach Bio have successfully attracted new investor funding. The new capital will enable the companies, for example, to expand their research and development activities. Tubulis and Eisbach develop new therapeutic approaches and active agents for cancer treatment, ...
"I am excited by the progress the Tubulis team has made over the last few years toward this major milestone"
24-Jun-2024
Groundbreaking innovations by researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) provided the basis for the development of an antibody-drug conjugate (ADC) by the company Tubulis, which is now being used in a Phase I/IIa trial in tumour patients. Thanks to an ...
"This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space"
18-Mar-2024
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led byEQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation from new US-based funds, Frazier Life ...
Focus on accelerated development of differentiated antibody-drug conjugates therapeutics for solid tumors
04-Apr-2023
BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. (DualityBio), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”) therapeutics to treat patients with cancer and autoimmune diseases, announced that the companies have ...
"Araris continues to make waves in the industry with its pioneering linker technology, enabling fast and precise production of ADCs"
10-Oct-2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. The round was co-led by 4BIO Capital and Pureos Bioventures, with participation ...
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours
21-Jun-2022
Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million ($3M) with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of ...
Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
05-May-2022
Tubulis announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), ...
Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity
08-Dec-2021
Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, announces that it has closed an €87 million series A financing round. The round was led by Pontifax Venture Capital and includes RA Capital ...
